However, despite initial robust responses to first- and second-generation EGFR-TKIs, a considerable number of NSCLC patients develop acquired resistance during EGFR-TKI treatment within 9 to 14 months after starting treatment [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.